Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients
NCT ID: NCT02707263
Last Updated: 2017-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2016-03-31
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin
NCT02970032
Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery
NCT01608906
Thromboprophylaxis in Critically Ill Patients
NCT00437697
Anti-factor Xa Based Venous Thromboembolism Prophylaxis
NCT05221879
Inpatient Monitoring of Unfractionated Heparin
NCT06329921
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intravenous continuous infusion of heparin (IV UFH)
Heparin will be administered intravenously.
intravenous continuous infusion of heparin (IV UFH)
Subcutaneous heparin
Heparin will be subcutaneously administered.
Subcutaneous Heparin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intravenous continuous infusion of heparin (IV UFH)
Subcutaneous Heparin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High-risk for Venous Thromboembolism (VTE) ≥ 1 of the following:
* Body Mass Index (BMI) ≥ 30 kg/m2
* Personal or family history of VTE
* Receiving vasopressors
Exclusion Criteria
* Evidence of deep vein thrombosis (DVT) on ultrasonography at admission
* Indwelling intrathecal, epidural, or other indwelling deep catheters
* Recent (\< 3 months) International Society of Thrombosis and Haemostasis (ISTH) major bleeding13
* Recent (\< 3 months) major trauma
* Recent (\< 3 months) neurosurgery or orthopedic surgery Pregnancy
* Contraindication to heparin or heparin products
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Papadopoulos, MD
Role: PRINCIPAL_INVESTIGATOR
New York University Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York University School of Medicine
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-01051
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.